Supernus Pharmaceuticals, Inc.
As of Oct 22, 2026, Supernus Pharmaceuticals is in Stage 4, the downtrend phase, now in week 6 (since Sep 14, 2026). It closed at $42.07, 26.2% below its 52-week high and below its 200-day average, which is falling.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SUPN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SUPN among Drug Manufacturers - Specialty & Generic39th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …39 | SUPN | Stage 4 · wk 6 | 41 | −3.0% |
Supernus Pharmaceuticals: quick answers
What stage is Supernus Pharmaceuticals in?
As of Oct 22, 2026, Supernus Pharmaceuticals (SUPN) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 14, 2026 and is in week 6. What the four stages mean
Is Supernus Pharmaceuticals in an uptrend?
No. Supernus Pharmaceuticals is in a Stage 4 downtrend. It trades 11.6% below its 200-day average, which is falling.
How far is Supernus Pharmaceuticals from its 52-week high?
Supernus Pharmaceuticals closed at $42.07 on Oct 22, 2026, 26.2% below its 52-week high of $57.00. Its 52-week low is $37.88.
How has Supernus Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Supernus Pharmaceuticals is down 17.0% over the past year and down 15.0% so far in 2026.
Which sector and industry is Supernus Pharmaceuticals in?
Supernus Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.